Terms: = Skin cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
1026 results:
1. Decoding dynamic interactions between egfr-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
2. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
3. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract] [Full Text] [Related]
4. Diseases categorized as autoinflammatory keratinization diseases (AiKDs), and their pathologies and treatments.
Akiyama M
Nagoya J Med Sci; 2024 Feb; 86(1):1-15. PubMed ID: 38505726
[TBL] [Abstract] [Full Text] [Related]
5. Nanobody-mediated targeting of zinc phthalocyanine with polymer micelles as nanocarriers.
Mesquita B; Singh A; Prats Masdeu C; Lokhorst N; Hebels ER; van Steenbergen M; Mastrobattista E; Heger M; van Nostrum CF; Oliveira S
Int J Pharm; 2024 Apr; 655():124004. PubMed ID: 38492899
[TBL] [Abstract] [Full Text] [Related]
6. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
[TBL] [Abstract] [Full Text] [Related]
7. Sunset Yellow protects against oxidative damage and exhibits chemoprevention in chemically induced skin cancer model.
Singh S; Yadav S; Cavallo C; Mourya D; Singh I; Kumar V; Shukla S; Shukla P; Chaudhary R; Maurya GP; Müller RLJ; Rohde L; Mishra A; Wolkenhauer O; Gupta S; Tripathi A
NPJ Syst Biol Appl; 2024 Mar; 10(1):23. PubMed ID: 38431714
[TBL] [Abstract] [Full Text] [Related]
8. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract] [Full Text] [Related]
9. Mechanism of action of adapalene for treating egfr-TKI-induced skin disorder.
Mimura C; Nagano T; Miwa N; Matsumura K; Yamada J; Satoh H; Suraya R; Hazama D; Tamura D; Yamamoto M; Tachihara M; Nishimura Y; Kobayashi K
Thorac Cancer; 2024 Mar; 15(9):722-729. PubMed ID: 38379420
[TBL] [Abstract] [Full Text] [Related]
10. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (egfr) Monoclonal Antibody-Induced skin Fissure: A Single Institutional Case Series.
Okunaka M; Kotani D; Mishima S; Nakamura M; Kawazoe A; Bando H; Yoshino T; Shitara K
Integr Cancer Ther; 2024; 23():15347354231225962. PubMed ID: 38240253
[TBL] [Abstract] [Full Text] [Related]
11. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Hung LJ; Hsu PC; Yang CT; Kuo CS; Chang JW; Huang CY; Chang CF; Wu CE
Aging (Albany NY); 2024 Jan; 16(1):550-567. PubMed ID: 38194721
[TBL] [Abstract] [Full Text] [Related]
12. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract] [Full Text] [Related]
13.
Jia Y; Guan Z; Liu C; Huang M; Li J; Feng J; Shen B; Yang G
Microbiol Spectr; 2024 Jan; 12(1):e0222723. PubMed ID: 38059627
[No Abstract] [Full Text] [Related]
14. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
Support Care Cancer; 2023 Dec; 32(1):8. PubMed ID: 38055053
[TBL] [Abstract] [Full Text] [Related]
15. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.
Takahashi H; Saito Y; Sugawara K; Sato M; Tairabune T; Ujiie H; Asaka J; Kudo K
Cancer Chemother Pharmacol; 2024 Apr; 93(4):319-328. PubMed ID: 38017207
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis.
Pham JP; Rodrigues A; Goldinger SM; Sim HW; Liu J
Exp Dermatol; 2024 Jan; 33(1):e14978. PubMed ID: 37971204
[TBL] [Abstract] [Full Text] [Related]
17. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
18. KIF22 promotes the proliferation and glycolysis of melanoma by activating egfr/STAT3 signaling.
Zhong Z; Zhong H
Clinics (Sao Paulo); 2023; 78():100307. PubMed ID: 37944197
[TBL] [Abstract] [Full Text] [Related]
19. A phase 2 trial combining afatinib with cetuximab in patients with egfr exon 20 insertion-positive non-small cell lung cancer.
van Veggel BAMH; van der Wekken AJ; Paats MS; Hendriks LEL; Hashemi SMS; Daletzakis A; van den Broek D; Bosch LJW; Monkhorst K; Smit EF; de Langen AJ
Cancer; 2024 Mar; 130(5):683-691. PubMed ID: 37905752
[TBL] [Abstract] [Full Text] [Related]
20. Sotorasib plus Panitumumab in Refractory Colorectal cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract] [Full Text] [Related]
[Next]
